Aemetis (NASDAQ:AMTX) Upgraded at StockNews.com

StockNews.com upgraded shares of Aemetis (NASDAQ:AMTX - Free Report) to a sell rating in a research note issued to investors on Friday.

Separately, HC Wainwright reissued a "buy" rating and set a $28.00 price target on shares of Aemetis in a research note on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $12.95.

Aemetis Stock Performance

Shares of Aemetis stock traded up $0.15 on Friday, hitting $2.97. 761,389 shares of the company traded hands, compared to its average volume of 705,794. Aemetis has a 52 week low of $2.10 and a 52 week high of $7.03. The business has a 50-day simple moving average of $3.27 and a 200 day simple moving average of $2.98. The stock has a market capitalization of $147.71 million, a P/E ratio of -1.31 and a beta of 1.35.

Aemetis (NASDAQ:AMTX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.09. The company had revenue of $81.44 million during the quarter, compared to the consensus estimate of $77.79 million. During the same quarter in the prior year, the firm posted ($0.59) earnings per share. Research analysts expect that Aemetis will post -2.02 earnings per share for the current year.

Institutional Investors Weigh In On Aemetis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMTX. FMR LLC increased its position in shares of Aemetis by 68.2% during the 3rd quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company's stock valued at $52,000 after purchasing an additional 9,137 shares during the last quarter. Hutchinson Capital Management CA purchased a new stake in shares of Aemetis in the second quarter valued at $70,000. Barclays PLC lifted its holdings in shares of Aemetis by 274.6% in the 3rd quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company's stock worth $109,000 after acquiring an additional 34,816 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Aemetis by 2,837.1% during the 2nd quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company's stock worth $157,000 after purchasing an additional 50,528 shares during the period. Finally, Wellington Management Group LLP bought a new position in Aemetis during the 3rd quarter valued at about $177,000. 27.02% of the stock is currently owned by hedge funds and other institutional investors.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.